Highest-materiality recent filing
Harvard Apparatus Regenerative Technology treats first patient in Phase 1 esophageal implant trial
First patient treated with Cellspan Esophageal Implant (CEI) in Phase 1 clinical trial at Mayo Clinic.
Harvard Apparatus receives $300K bridge loan from CEO Junli He at 8% interest
Loan of $300,000 from Chairman/CEO Junli He; annual 8% fixed interest rate.
Harvard Apparatus raises $2.0M via private placement of 1.25M shares at $1.60/share
Sold 1,250,000 shares of common stock to accredited investors for aggregate proceeds of ~$2.0M.
Reverse stock split amendment approved; Board authorized to determine ratio and timing at discretion.
Exclusive distribution of consumer health/dietary supplements from Nov 1, 2024 to Dec 31, 2030; auto-renews for 6 years if targets met.
Aggregate purchase price of $1.5 million for 367,767 shares at $4.03 per share in a private placement.
Harvard Apparatus Regenerative Technology enters $500K bridge note with CEO Junli He at 8% interest
Bridge note for $500,000 from Chairman/CEO Junli He; 8% annual interest on 360-day basis.
Biostage raises ~$6M via private placement of 1M shares at $6.00; preferred stock converted
Gross proceeds ~$6M from sale of 1,000,967 shares at $6.00/share; $3.6M received by Apr 5, 2023.
Biostage appoints Jerry He as CEO, replacing David Green; sets compensation terms
Jerry He appointed Chairman and CEO effective March 1, 2023; David Green remains on board.
Biostage appoints Jerry He as Chairman and CEO; David Green remains on Board
Jerry He appointed Chairman and CEO effective March 1, 2023, replacing David Green.
Biostage CEO David Green made permanent; new agreement includes $300k salary, stock options
Interim tag removed; David Green named permanent CEO effective January 11, 2023.
Biostage selects IQVIA as CRO for FDA-approved esophageal implant trial
IQVIA, a global CRO with GI and cell-therapy trial experience, to manage Biostage's first clinical trial.
Biostage appoints Joseph Damasio as CFO; $250K salary, 116K-share option grant
Mr. Damasio appointed CFO effective August 8, 2022; brings capital raising and biotech finance experience.
Biostage shareholders approve reverse stock split ratio of 1-for-1.25 to 1-for-5
Proposal to amend charter to effect reverse stock split approved with 7,072,052 votes for, 196,116 against, 742 abstained.
Biostage issues $4M Series E Convertible Preferred to Harvard Bioscience to satisfy indemnification
Issued 4,000 shares of Series E Preferred at $1,000/share to HBIO on June 10, 2022, to settle $4M indemnification obligations.
Biostage Q1 net loss widens to $2.2M; settles lawsuit, raises $5.1M placement
Q1 net loss of $2.2M ($0.20 per share) vs $0.9M loss ($0.09) in Q1 2021; G&A up $1.4M on legal costs.
Biostage raises $5.1M in private placement to advance esophageal implant clinical trial
Raised ~$5.1M from new and existing investors via 854,771 shares and warrants for 427,390 shares at $5.92/unit.
Biostage settles wrongful death litigation; to issue $4M convertible preferred to HBIO
Biostage settles 2017 wrongful death suit; total costs estimated at ~$6M, $5.7M unpaid.
Biostage FY2021 net loss widens to $8.0M on $3.3M litigation charge and higher legal costs
Q4 2021 net loss of $5.9M ($0.55/share) vs $1.0M loss in Q4 2020; FY2021 loss $8.0M ($0.79/share).
Biostage wins court order requiring insurer to pay legal defense; to host investor webinar Jan 27
Court ordered Medmarc to continue paying Biostage's legal defense in a wrongful death suit over a tracheal implant, finding Medmarc breached its duty and awarding attorneys' fees.
Biostage highlights first-in-human esophageal success, FDA-approved IND, founder CEO return
First-in-human esophageal implant at Mayo Clinic; paper published Aug 2021 concludes 'considerable clinical use'.
Biostage appoints David Green as interim CEO; he invests $250,000 in private placement
David Green appointed Interim CEO and Chairman; Jason Chen becomes Vice Chairman.
Biostage reports Q3 net loss of $0.8M; cash $2.0M, funds ops into Q2 2022
Net loss for Q3 2021 was $0.8M ($0.8 per share) vs $0.7M ($0.07 per share) in Q3 2020.
On Sept 15, 2021, a product liability insurer denied coverage for the 2017 wrongful death suit and will stop defending after Sept 30, 2021.
Biostage raises $2.6M in private placements, appoints Jerry He to board
Raised $2.0M in Sept 2021 from DST Capital and An Zhang in private placement of 1M shares and warrants for 500K shares at $2.00 per unit.
On August 26, 2024, Mao Zhang, the Founder and Chief Executive Officer of Stellars Capital, joined the Board of Directors (the “Board”) of the Company as a Class I director.
On April 5, 2023, Ron Packard, the Chief Executive officer of Pansophic Learning, joined the Board of Directors (the “Board”) of the Company as a Class II director.
the Company’s existing director, Junli (Jerry) He, was appointed Chairman and Chief Executive Officer of the Company, in replacement of David Green in such roles.
the Company’s existing director, Junli (Jerry) He, was appointed Chairman and Chief Executive Officer of the Company, in replacement of David Green in such roles.
in replacement of David Green in such roles.
Junli (Jerry) He, was appointed Chairman and Chief Executive Officer of the Company, in replacement of David Green in such roles.
Effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately
Effective as of August 8, 2022, Biostage, Inc. (the Company) appointed Joseph L. Damasio, Jr., as Chief Financial Officer.
Mr. Green also joined the Board as a Class II director and was appointed Chairman of the Board.
Effective as of November 26, 2021, the Company appointed Mr. Green as Interim Chief Executive Officer.
the Company’s existing Chairman, Jason Chen, was appointed Vice Chairman of the Board.
On September 1, 2021, Junli He, the Executive Vice Chairman of Bright Scholar Holdings, joined the Board of Directors (the “Board”) of the Company as a Class I director.
Max materiality 0.75 · Median 0.60 · Most common event other_material